D. Western Therapeutics Institute Inc. (4576) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for D. Western Therapeutics Institute Inc. (4576:JPX), powered by AI.

Current Price
¥70
P/E Ratio
-5.3
Market Cap
3.4B
Sector
Healthcare
What is the D. Western Therapeutics Institute Inc. stock price forecast?

D. Western Therapeutics Institute Inc. is currently trading at ¥70. View real-time AI analysis on Alpha Lenz.

What is D. Western Therapeutics Institute Inc. insider trading activity?

View the latest insider trading data for D. Western Therapeutics Institute Inc. on Alpha Lenz.

What is D. Western Therapeutics Institute Inc.'s P/E ratio?

D. Western Therapeutics Institute Inc.'s P/E ratio is -5.3.

D. Western Therapeutics Institute Inc.

JPX · 4576
¥70+2(+2.94%)Market closedJPX regular session 09:00–15:00 JST
Ask about D. Western Therapeutics Institute Inc.'s future dividend policy...
Alpha Chat Insight

D. Western Therapeutics Institute Inc. trades at a P/E of -5.3 (undervalued) with modest ROE of -58.3%.

Ask for details

Company Overview

D. Western Therapeutics Institute Inc. is a biopharmaceutical company involved in the research, development, and commercialization of therapeutic products. With a focus on innovative drug discovery, the institute works on creating compounds that address unmet medical needs. The company's portfolio includes candidates targeting various ocular diseases and conditions, catering to a niche yet crucial sector within the healthcare industry. By leveraging scientific expertise and cutting-edge technology, D. Western Therapeutics Institute aims to enhance treatment outcomes and improve patient quality of life. The company's role in the financial market is significant, as it contributes to advancements in pharmaceuticals and potentially offers new products that can transform existing treatment paradigms. Through partnerships, collaboration with research institutes, and investment in biotechnology, the company exemplifies the integration of scientific discovery and practical application in the dynamic field of biopharmaceutical innovation.

CEOMr. Yuichi Hidaka
SectorHealthcare
IndustryBiotechnology
Employees21

Company Statistics

FY 2025

Profile

¥3,354,990,030Market Cap
¥387,620,000Revenue
0.00Shares Out
21Employees

Margins

89.97%Gross
-148.12%EBITDA
-159.92%Operating
-162.66%Pre-Tax
-163.07%Net

Valuation

-5.31P/E
2.34P/B
8.66EV/Sales
-3.92EV/EBITDA
-6.76P/FCF

Growth (CAGR)

-4.72%Rev 3Yr
1.74%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-32.93%ROA
-58.28%ROE
-32.39%ROIC

Financial Health

¥1,709,790,000Cash & Cash Equivalents
¥-975,778,000Net Debt
51.13%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

D. Western Therapeutics Institute Inc. (ticker: 4576) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 21 employees. Market cap is $3.4B.

The current price is 70 with a P/E ratio of -5.31x and P/B of 2.34x.

ROE is -58.28% and operating margin is -159.92%. Annual revenue is $388M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
D. Western Therapeutics Institute Inc. (4576) Stock Forecast 2026 ¥70 — Price, Financials & Analyst Targets | Alpha Lenz